Shitara K, Janjigian Y, Ajani J, Moehler M, Yao J, Wang X
Nat Med. 2025; .
PMID: 40055521
DOI: 10.1038/s41591-025-03575-0.
Zhang M, Li J, Yan K, Zhou H, Mei S, Wang B
Proc Natl Acad Sci U S A. 2025; 122(8):e2422731122.
PMID: 39964714
PMC: 11874271.
DOI: 10.1073/pnas.2422731122.
Martinenaite E, Lecoq I, Aaboe-Jorgensen M, Ahmad S, Perez-Penco M, Glockner H
J Immunother Cancer. 2025; 13(1).
PMID: 39880485
PMC: 11781113.
DOI: 10.1136/jitc-2024-009930.
Wang J, Chen Y, Sun Y, Liu H, Du R, Wang X
Int J Biol Sci. 2025; 21(2):671-684.
PMID: 39781458
PMC: 11705627.
DOI: 10.7150/ijbs.95723.
Cole M, Anastasiou P, Lee C, Yu X, de Castro A, Roelink J
Sci Adv. 2024; 10(44):eadl6464.
PMID: 39485838
PMC: 11529713.
DOI: 10.1126/sciadv.adl6464.
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A
Nature. 2024; 635(8038):462-471.
PMID: 39385035
PMC: 11560846.
DOI: 10.1038/s41586-024-07943-7.
Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.
Anastasiou P, Moore C, Rana S, Tomaschko M, Pillsbury C, de Castro A
Nat Commun. 2024; 15(1):8146.
PMID: 39322643
PMC: 11424635.
DOI: 10.1038/s41467-024-52324-3.
Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial.
Ager C, Obradovic A, McCann P, Chaimowitz M, Wang A, Shaikh N
medRxiv. 2024; .
PMID: 39314954
PMC: 11419205.
DOI: 10.1101/2024.09.09.24313308.
Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations.
Ge J, Yin X, Chen L
Front Immunol. 2024; 15:1457189.
PMID: 39290699
PMC: 11405253.
DOI: 10.3389/fimmu.2024.1457189.
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.
Chand D, Savitsky D, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P
Cancer Discov. 2024; 14(12):2407-2429.
PMID: 39083809
PMC: 11609826.
DOI: 10.1158/2159-8290.CD-24-0190.
A combined radio-immunotherapy regimen eradicates late-stage tumors in mice.
Rakhmilevich A, Tsarovsky N, Felder M, Zaborek J, Moram S, Erbe A
Front Immunol. 2024; 15:1419773.
PMID: 39076988
PMC: 11284032.
DOI: 10.3389/fimmu.2024.1419773.
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment.
Azar F, Deforges J, Demeusoit C, Kleinpeter P, Remy C, Silvestre N
J Immunother Cancer. 2024; 12(7).
PMID: 39060022
PMC: 11284822.
DOI: 10.1136/jitc-2024-009302.
Anti-CTLA-4 m2a Antibody Exacerbates Cardiac Injury in Experimental Autoimmune Myocarditis Mice By Promoting Ccl5-Neutrophil Infiltration.
Wu M, Yang Y, Cai Y, Jiang S, Xiao H, Miao C
Adv Sci (Weinh). 2024; 11(34):e2400486.
PMID: 38978328
PMC: 11425905.
DOI: 10.1002/advs.202400486.
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
Willoughby J, Dou L, Bhattacharya S, Jackson H, Seestaller-Wehr L, Kilian D
J Immunother Cancer. 2024; 12(7).
PMID: 38964788
PMC: 11227834.
DOI: 10.1136/jitc-2023-008677.
Exploiting temporal aspects of cancer immunotherapy.
Zemek R, Anagnostou V, Pires da Silva I, Long G, Lesterhuis W
Nat Rev Cancer. 2024; 24(7):480-497.
PMID: 38886574
DOI: 10.1038/s41568-024-00699-2.
Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma.
Habib S, Osborn G, Willsmore Z, Chew M, Jakubow S, Fitzpatrick A
Expert Rev Clin Immunol. 2024; 20(8):895-911.
PMID: 38533720
PMC: 11286214.
DOI: 10.1080/1744666X.2024.2326626.
Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols.
Barboy O, Bercovich A, Li H, Eyal-Lubling Y, Yalin A, Shapir Itai Y
Nat Cancer. 2024; 5(5):742-759.
PMID: 38429414
DOI: 10.1038/s43018-024-00734-z.
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells.
Guan X, Hu R, Choi Y, Srivats S, Nabet B, Silva J
Nature. 2024; 627(8004):646-655.
PMID: 38418879
PMC: 11139643.
DOI: 10.1038/s41586-024-07121-9.
CTLA-4: Checkpoints beyond the membrane.
Buchan S
Mol Ther. 2024; 32(2):279-281.
PMID: 38237584
PMC: 10861949.
DOI: 10.1016/j.ymthe.2024.01.002.
Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges.
Lim S, Beers S, Al-Shamkhani A, Cragg M
Clin Cancer Res. 2023; 30(9):1712-1723.
PMID: 38153346
PMC: 7615925.
DOI: 10.1158/1078-0432.CCR-23-1014.